Incannex Healthcare Limited rings the Closing Bell at the NASDAQ
Incannex Healthcare Limited lists on the NASDAQ. Mr Joel Latham, Managing Director & CEO of Incannex rings the Closing Bell… Read more
Incannex Healthcare Limited lists on the NASDAQ. Mr Joel Latham, Managing Director & CEO of Incannex rings the Closing Bell… Read more
“Considering weakened market conditions on the Nasdaq and more specifically the Nasdaq Biotech Index, which has corrected circa 20% in… Read more
Incannex Healthcare Limited (ASX:IHL), (‘Incannex” or the ‘Company’) a clinical stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and… Read more
As announced on 18 August 2021, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’) filed a registration statement on… Read more
“Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine, or… Read more
Highlights: • Phase 2a psilocybin-assisted therapy for Generalised Anxiety Disorder clinical trial has received approval to proceed from the Monash… Read more
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce: 1. that… Read more
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it… Read more
Clinical stage cannabinoid and psychedelic medicine development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’) is pleased to… Read more